Becton, Dickinson and Company $BDX Shares Bought by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 24.9% during the 2nd quarter, HoldingsChannel reports. The firm owned 12,155 shares of the medical instruments supplier’s stock after acquiring an additional 2,421 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Becton, Dickinson and Company were worth $2,094,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in BDX. Saudi Central Bank bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth approximately $26,000. Smallwood Wealth Investment Management LLC bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth approximately $27,000. Alpine Bank Wealth Management bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC raised its stake in Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 99 shares in the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA bought a new stake in Becton, Dickinson and Company during the 1st quarter valued at $31,000. Institutional investors own 86.97% of the company’s stock.

Insider Activity

In related news, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,023 shares of company stock valued at $562,036 in the last three months. 0.36% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

BDX has been the topic of several recent analyst reports. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday. Argus lifted their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Finally, Royal Bank Of Canada started coverage on Becton, Dickinson and Company in a research report on Thursday, September 25th. They set a “sector perform” rating and a $211.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $186.41 on Friday. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $53.43 billion, a price-to-earnings ratio of 33.53, a PEG ratio of 1.48 and a beta of 0.25. The stock’s fifty day simple moving average is $190.07 and its 200 day simple moving average is $186.32. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.32 billion for the quarter. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s payout ratio is currently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.